Adenovirus Clinical Trial
Official title:
Interest of Rapid Typing in Adenovirus Infections: Sensitivity and Specificity, Study of the Association Clinical Characteristics and Viral Type.
Proposal of a "rapid typing" technique by a new real-time PCR method, simpler, faster and cheaper than nucleotide sequencing (reference method) for rapid typing in Adenovirus infections.
Adenoviruses cause many infections, mainly respiratory and gastroenteric, in pediatrics.
They also behave as opportunistic agents in 10% of hematopoietic stem cell recipients. In
these immunocompromised persons, these infections are all the more frequent as the graft is
of placental origin and the recipient a child (20%). They are then willingly disseminated and
potentially deadly; their treatment is based on cidofovir, a viral agent that is very
sensitive to handling.
Adenoviruses, which have a high genetic diversity, are classified into 7 types. According to
some observations, still limited, some types of Adenovirus would show a higher pathogenicity
(types C and A). Thus, viral typing may be prognostic for immunocompromised patients,
justifying the initiation of an earlier specific treatment when identifying certain more
pathogenic viral types, in addition to measuring the viral load, already performed by
quantitative PCR.
For this purpose, this study proposes a "fast typing" technique by new real-time PCR method,
simpler, faster and cheaper than nucleotide sequencing, reference method.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
| Recruiting |
NCT03665675 -
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
|
Early Phase 1 | |
| Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
| Recruiting |
NCT03266627 -
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
|
Phase 2 | |
| Not yet recruiting |
NCT03325517 -
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics
|
N/A | |
| Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
| Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
| Withdrawn |
NCT00448994 -
Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients
|
N/A | |
| Recruiting |
NCT06299813 -
Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection
|
Phase 3 | |
| Enrolling by invitation |
NCT06027879 -
Anti-viral T-cell Therapy by Gamma Capture
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02779439 -
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
|
Phase 1 | |
| Terminated |
NCT02420080 -
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
|
N/A | |
| Active, not recruiting |
NCT01945814 -
Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)
|
Phase 1 | |
| Completed |
NCT01535885 -
Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV
|
Phase 1 | |
| Terminated |
NCT03339401 -
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
|
Phase 2 | |
| Withdrawn |
NCT01584037 -
Adenovirus Vaccine Pregnancy Registry
|
N/A | |
| Withdrawn |
NCT03532035 -
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
|
Phase 2 | |
| Recruiting |
NCT02008812 -
Ad Sensor-based Real-time Diagnosis of Adenovirus
|
N/A | |
| Active, not recruiting |
NCT04364178 -
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05664126 -
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
|
Phase 2 |